for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Genmab Announces Favorable Topline Results From Phase 2 Clinical Trial Of Tisotumab Vedotin

June 29 (Reuters) - Genmab A/S:

* REG-GENMAB ANNOUNCES VERY FAVORABLE TOPLINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF TISOTUMAB VEDOTIN IN RECURRENT OR METASTATIC CERVICAL CANCER

* GENMAB AND SEATTLE GENETICS PLAN TO DISCUSS RESULTS WITH U.S. FOOD AND DRUG ADMINISTRATION

* TISOTUMAB VEDOTIN IS BEING DEVELOPED IN COLLABORATION WITH SEATTLE GENETICS Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up